Clinical Study of the Combination of Afatinib and AC Chemotherapy in the Treatment of Advanced Sensitive EGFR Mutated Lung Adenocarcinoma
Objective To explore the clinical efficacy of the combination of afatinib,pemetrexed,and carboplatin(AC)chemotherapy regimen in the treatment of advanced sensitive epidermal growth factor receptor(EGFR)mutated lung adenocarci-noma.Methods This study was a prospective randomized controlled study,52 patients with advanced sensitive EGFR mutation lung adenocarcinoma were selected and randomly divided into the control group(26 cases,AC chemotherapy regimen treatment)and the observation group(26 cases,treated with AC chemotherapy regimen and afatinib)using a random number table method,all groups were treated continuously for 6 courses.The efficacy,levels of tumor markers[carcinoembryonic antigen(CEA),cytok-eratin 19 fragment antigen 21-1(CYFRA21-1)],and EGFR levels were compared between the 2 groups.The incidence of side effects during treatment were compared between the 2 groups,and the survival of patients followed up for 12 months were statisti-cally analyzed.Results After 6 courses of treatment,the remission rate in the control group was lower than that in the observation group(P＜0.05).The levels of CEA and CYFRA21-1 in the control group were higher than those in the observation group(P＜0.05).The EGFR level in the control group was higher than that in the observation group(P＜0.05).Within 12 months of fol-low-up,the control group had a shorter progression free survival time than the observation group(P＜0.05).Comparison of total survival time between the 2 groups based on Log Rank test(P＜0.05).Conclusion The combination of AC chemotherapy and afatinib has a significant effect on advanced sensitive EGFR mutated lung adenocarcinoma patients,which can reduce EGFR levels and tumor marker levels,and prolong survival time.
NETL
NSTL
万方数据
